GLP‑1 drugs move from medicine to economics
The GLP‑1 obesity drug market is shifting into an economic story: India’s loss of semaglutide patents has spurred a generics rush that could sharply lower prices in large markets. At the same time, research shows genetics influence who benefits and that both drug and surgical weight loss can reduce muscle as well as fat — developments that could push payers toward more targeted coverage decisions. (economictimes.indiatimes.com) (vox.com) (bbc.com) (sciencedaily.com)
Semaglutide started as a drug story and is turning into a pricing story. In India, a key patent on semaglutide expired in March 2026, and more than a dozen drugmakers moved in almost immediately with generic versions and launch plans. (economictimes.indiatimes.com 1) (economictimes.indiatimes.com 2) That matters because semaglutide is the ingredient behind Ozempic and Wegovy, two of the drugs that turned obesity treatment from a niche market into a global scramble. In a landmark New England Journal of Medicine trial, adults taking semaglutide lost an average 14.9% of body weight over 68 weeks, versus 2.4% on placebo. (nejm.org) India is the first big test of what happens when that blockbuster chemistry stops being protected and starts being copied. Economic Times reported that some Indian launches were expected at prices as low as about ₹1,290 per month, and one early generic was expected to come in up to 60% below Novo Nordisk’s Ozempic price. (economictimes.indiatimes.com) (pharma.economictimes.indiatimes.com) Novo Nordisk has already responded with price cuts in India. Economic Times reported that, effective April 1, Novo cut Ozempic prices by 36% and Wegovy prices by 48% as generic competition intensified. (economictimes.indiatimes.com) This is why the market is starting to look less like luxury medicine and more like a fight over who gets covered, at what price, and for how long. Vox argued that India’s generic shift could become a model for wider access in lower-cost markets if manufacturing scales and regulators allow broad competition. (vox.com) At the same time, the science is getting less simple. A Nature paper published on April 8 studied almost 28,000 people and found genetic variants linked to both how much weight people lost on glucagon-like peptide-1 drugs and who was more likely to get stomach side effects. (nature.com 1) (nature.com 2) That pushes the market in a different direction from cheap generics. If two patients taking the same drug can have different results because of differences in genes tied to the drug target, insurers have a stronger case for saying coverage should be targeted instead of open-ended. (nature.com 1) (nature.com 2) There is another complication: the weight lost is not all fat. A University of Hong Kong study summarized by ScienceDaily found that glucagon-like peptide-1 receptor agonists reduced more fat mass than muscle mass, but still lowered both, which means the body can get lighter while also getting weaker if protein intake and resistance training lag. (sciencedaily.com) Surgery shows a similar tradeoff in a different form. The National Institute of Diabetes and Digestive and Kidney Diseases says bariatric surgery produces large long-term weight losses, with gastric bypass patients in one long study averaging about 28% below starting weight after 7 years, but surgery also changes body composition rather than removing only fat. (niddk.nih.gov) (niddk.nih.gov) So the next fight is not just whether these drugs work, because they clearly do for many people. The next fight is whether health systems treat semaglutide like a mass-market generic pill, a precision medicine that should be matched to the right patient, or a long-term therapy that also requires nutrition and strength-preserving care around it. (nejm.org) (nature.com) (sciencedaily.com)
